Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.

MLA

Caro, Luzelena, et al. “Pharmacokinetics of Elbasvir and Grazoprevir in Subjects with End-Stage Renal Disease or Severe Renal Impairment.” European Journal of Clinical Pharmacology, vol. 75, no. 5, May 2019, pp. 665–75. EBSCOhost, https://doi.org/10.1007/s00228-018-2585-3.

APA

Caro, L., Wenning, L., Feng, H.-P., Guo, Z., Du, L., Bhagunde, P., Fandozzi, C., Panebianco, D., Marshall, W. L., Butterton, J. R., Iwamoto, M., & Yeh, W. W. (2019). Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. European Journal of Clinical Pharmacology, 75(5), 665–675. https://doi.org/10.1007/s00228-018-2585-3

Chicago

Caro, Luzelena, Larissa Wenning, Hwa-Ping Feng, Zifang Guo, Lihong Du, Pratik Bhagunde, Christine Fandozzi, et al. 2019. “Pharmacokinetics of Elbasvir and Grazoprevir in Subjects with End-Stage Renal Disease or Severe Renal Impairment.” European Journal of Clinical Pharmacology 75 (5): 665–75. doi:10.1007/s00228-018-2585-3.